Juvenile Diabetes Research Foundation (JDRF): Innovative Strategies To Demonstrate “Immunological Proof-of-Mechanism” And To Explore Early Outcome Measures In Immunotherapy Trials (LOI)

1) Define a measure or measures that will allow evaluation of candidate immune therapies for treatment effect, in a shorter timescale and with fewer subjects than current practice.

2) Explore early outcome measures that are surrogates for clinical efficacy in immunotherapy trials.

3) Define a lower burden outcome measure that may be frequently sampled with easier tools and technologies than currently available. 4) Define a measure/score for therapeutic effect, incorporating measures that represent early alterations in disease course after interventions. 5) Other novel approaches to determine early readouts of immune therapeutic effect and/or link such to improved, earlier outcomes in T1D immunotherapy trials.

Funding:

strong cross functional teams will be given highest priority and a maximum budget of up to $2M total (including 10% indirect costs, typically for a 3year period) may be proposed.

Pilot and feasibility studies on compelling topics, when the pilot is a clear first step to a potential larger effort may be submitted. Each pilot project may request up to total $110,000 USD [typically $75k - $110k] per year for one year (including 10 % indirect costs).

(Nonprofit)

http://grantcenter.jdrf.org/rfa/innovative-strategies-to-demonstrate-immunological-proof-of-mechanism-and-to-explore-early-outcome-measures-in-immunotherapy-trials/